ANDA 90776, held by Actavis Elizabeth. Duloxetine Hydrochloride.
As of Nov 16, 2026, ANDA 90776 (Duloxetine Hydrochloride), held by Actavis Elizabeth, was first approved by FDA on Dec 17, 2013, with 7 approved supplements and 0 published complete response letters.
Duloxetine delayed-release capsules are indicated for the treatment of: Major depressive disorder in adults Generalized anxiety disorder in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain in adults Fibromyalgia in adults and pediatric patients 13 years of age and older Chronic musculoskeletal pain in adults Duloxetine delayed-release capsules are a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older Diabetic peripheral neuropathic pain (DPNP) in adults Fibr…
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 17, 2013 | Original application | Approved |
| Duloxetine HydrochlorideEQ 20MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 30MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| Duloxetine HydrochlorideEQ 60MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Rx |
| May 31, 2024 | Supplement 22Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 14Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| May 2, 2023 | Supplement 18Labeling · Standard review | Approved | None posted |
| Dec 17, 2013 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters